IDS-iSYS Total Testosterone Launch

We are pleased to announce the launch of the IDS-iSYS Total Testosterone assay in the European market – a fully automated assay for use with the IDS-iSYS Multi-Discipline Automated System.

The launch of the IDS-iSYS Total Testosterone assay is the latest addition to the new fertility (steroid hormones) portfolio.

The IDS-iSYS Total Testosterone assay measures a patient’s Testosterone level and offers clinicians an easy, non-invasive way to diagnose and treat disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, delayed or precocious puberty, impotence in males; in females hirsutism (excessive hair) and virilisation (masculinisation) due to tumours, polycystic ovaries, and adrenogenital syndromes.

In males Testosterone (17β-OH-4-androstene-3-one) is synthesised and secreted by the Leydig cells located in the interstitium of the testis, and in females testosterone is produced in various locations such as the ovaries, adrenal gland and peripheral tissues, with additional production due to inter-conversion from other steroid hormones. The secretion of testosterone is regulated by luteinising hormone (LH). Testosterone is found in circulation predominantly linked to carrier proteins, the most common of which being sex-hormone binding protein (SHBG).

The IDS-iSYS Total Testosterone assay is a key routine assay within the developing IDS fertility portfolio.